Obesity Treatment Drug Boom Drives Over 50% Surge in Sales, Global Pharma Raises Annual Guidance

Eli Lilly and Company (LLY) said on April 30 that its first-quarter 2026 results delivered revenue of $19.8 billion, up 56% year-over-year, and non-GAAP earnings per share of $8.26, a 170% increase.

The company credited the surge to strong demand for its obesity and diabetes therapies, including Mounjaro and Zepbound. In response, Lilly raised its full-year 2026 revenue guidance to $82 billion–$85 billion and increased its non-GAAP EPS target.

In early April, the U.S. Food and Drug Administration approved Foundayo, a once-daily, oral GLP-1 obesity treatment that can be taken without regard to meals or water, and U.S. sales have already commenced. Lilly also said it is advancing acquisition agreements with biotechs such as Orna Therapeutics and Ajax Therapeutics to strengthen its pipeline across diabetes, obesity, immunology, oncology and neuroscience.

Recently, Lilly announced a partnership with prescription discount platform GoodRx to expand patient access to its newly approved oral GLP-1 obesity treatments, Foundayo and Zepbound. The company is also pursuing a deal to acquire Ajax Therapeutics for up to $2.3 billion to bolster its blood-tumor portfolio, including hematologic cancers.

Headquartered in Indianapolis, Lilly is a global pharmaceutical leader that is rapidly expanding its anti-obesity footprint with GLP-1–based diabetes and weight-management therapies such as Mounjaro, Zepbound and Foundayo. The GLP-1 obesity-treatment market is currently dominated by a duopoly of Novo Nordisk and Lilly, and recent approvals of oral formulations are reshaping a market long centered on injectable medicines.